Literature DB >> 15537694

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

Alina S Bergshoeff1, Pieter L A Fraaij, Corrien Verweij, Annemarie M C van Rossum, Gwenda Verweel, Nico G Hartwig, Ronald de Groot, David M Burger.   

Abstract

OBJECTIVES: Zidovudine is often administered every 12 h in HIV-infected children, but so far no pharmacokinetic data are available for the administration of this agent every 12 h. We have evaluated the plasma pharmacokinetics of zidovudine administered every 8 h versus every 12 h in HIV-1-infected children.
METHODS: In HIV-1-infected children who switched from zidovudine every 8 h to every 12 h, a pharmacokinetic curve was recorded both before and after the switch. Zidovudine plasma levels were measured by HPLC. Pharmacokinetic parameters were calculated by non-compartmental methods.
RESULTS: Six HIV-1-infected children [median age (range) 7.8 (2.5-13.4) years] were included. In these patients, geometric mean ratios of AUC(0-24) and C(max) for zidovudine every 12 h versus every 8 h were not significantly different from 1.0.
CONCLUSIONS: The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537694     DOI: 10.1093/jac/dkh490

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?

Authors:  Floris Fauchet; Jean-Marc Treluyer; Elodie Valade; Sihem Benaboud; Emmanuelle Pannier; Ghislaine Firtion; Frantz Foissac; Naim Bouazza; Saik Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

2.  The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.

Authors:  Andrea N Edginton; Bhavank Shah; Michael Sevestre; Jeremiah D Momper
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

3.  Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.

Authors:  Floris Fauchet; Jean-Marc Treluyer; Pierre Frange; Saik Urien; Frantz Foissac; Naim Bouazza; Sihem Benaboud; Stephane Blanche; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

4.  Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain.

Authors:  Lopamudra Dutta; Biswajit Mukherjee; Tapash Chakraborty; Malay Kumar Das; Laboni Mondal; Sanchari Bhattacharya; Raghuvir H Gaonkar; Mita Chatterjee Debnath
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

5.  Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.

Authors:  Quirine Fillekes; Lindsay Kendall; Sabrina Kitaka; Peter Mugyenyi; Philippa Musoke; Milly Ndigendawani; Mutsa Bwakura-Dangarembizi; Diana M Gibb; David Burger; Ann Sarah Walker
Journal:  Pediatr Infect Dis J       Date:  2014-05       Impact factor: 2.129

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.